32208328|t|Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium.
32208328|a|PURPOSE: To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults. MATERIALS AND METHODS: Single-center, pilot study of a convenience sample of ICU adults with delirium treated with low-dose IV haloperidol. Patients were evaluated for delirium with the ICDSC every 8 h. Serum haloperidol concentrations were collected on ICU days 2-6, CYP2D6 and CYP3A4 genotypes were characterized and patients were categorized as extensive (EM), intermediate (IM) or poor metabolizers (PM). RESULTS: The 22 patients (median age 67 [IQR 48,77] years; median APACHE III 81[IQR 54,181]; CYP2D6 [EM = 12, IM = 7, PM = 3], CYP3A [EM = 18, IM = 4]) received a median [IQR] daily haloperidol dose of 3.0 [2.4, 4.5] mg. After adjusting for age, SOFA, and ICU day, neither an association between CYP2D6 (IM p = .67/PM p = .25) or CYP3A4 (IM p = .44) metabolizer status and serum haloperidol concentrations was found. After adjusting for age, SOFA, and ICU day, neither an association between daily haloperidol dose (p = .77) or ICDSC score (p = .13) and serum haloperidol concentrations was found. No patient experienced QTc interval prolongation (>=500 ms). CONCLUSIONS: This pilot study, the first to evaluate the pharmacogenomic response of low-dose haloperidol when used to treat delirium in the ICU, suggests CYP2D6/CYP3A4 metabolizer status does not affect the serum haloperidol concentrations.
32208328	37	48	haloperidol	Chemical	MESH:D006220
32208328	52	66	critically ill	Disease	MESH:D016638
32208328	79	87	delirium	Disease	MESH:D003693
32208328	155	166	haloperidol	Chemical	MESH:D006220
32208328	171	179	delirium	Disease	MESH:D003693
32208328	193	207	critically ill	Disease	MESH:D016638
32208328	309	317	delirium	Disease	MESH:D003693
32208328	343	354	haloperidol	Chemical	MESH:D006220
32208328	356	364	Patients	Species	9606
32208328	384	392	delirium	Disease	MESH:D003693
32208328	425	436	haloperidol	Chemical	MESH:D006220
32208328	484	490	CYP2D6	Gene	1565
32208328	495	501	CYP3A4	Gene	1576
32208328	535	543	patients	Species	9606
32208328	641	649	patients	Species	9606
32208328	698	701	III	Disease	MESH:C537189
32208328	718	724	CYP2D6	Gene	1565
32208328	752	757	CYP3A	Gene	1576
32208328	807	818	haloperidol	Chemical	MESH:D006220
32208328	921	927	CYP2D6	Gene	1565
32208328	955	961	CYP3A4	Gene	1576
32208328	1004	1015	haloperidol	Chemical	MESH:D006220
32208328	1123	1134	haloperidol	Chemical	MESH:D006220
32208328	1185	1196	haloperidol	Chemical	MESH:D006220
32208328	1226	1233	patient	Species	9606
32208328	1246	1271	QTc interval prolongation	Disease	MESH:D008133
32208328	1378	1389	haloperidol	Chemical	MESH:D006220
32208328	1409	1417	delirium	Disease	MESH:D003693
32208328	1439	1445	CYP2D6	Gene	1565
32208328	1446	1452	CYP3A4	Gene	1576
32208328	1498	1509	haloperidol	Chemical	MESH:D006220
32208328	Negative_Correlation	MESH:D006220	MESH:D003693
32208328	Negative_Correlation	MESH:D006220	MESH:D016638

